Hooi Ching Lim1, Shamit Soneji1, Róbert Pálmason2, Stig Lenhoff2, Thomas Laurell3, Stefan Scheding4,5. 1. Division of Molecular Hematology, Department of Laboratory Medicine, Lund Stem Cell Center, Lund University, BMC B12, Klinikgatan 26, 22184, Lund, Sweden. 2. Department of Hematology, Skåne University Hospital, Lund, Sweden. 3. Division of Nanobiotechnology and Lab-on-a-chip, Department of Biomedical Engineering, Lund University, Lund, Sweden. 4. Division of Molecular Hematology, Department of Laboratory Medicine, Lund Stem Cell Center, Lund University, BMC B12, Klinikgatan 26, 22184, Lund, Sweden. stefan.scheding@med.lu.se. 5. Department of Hematology, Skåne University Hospital, Lund, Sweden. stefan.scheding@med.lu.se.
Abstract
BACKGROUND: Infection and graft-versus-host disease (GvHD) are the major causes for mortality and morbidity of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Plasma-derived extracellular vesicles (EVs) contain disease-related proteins, DNAs and RNAs, and have recently been suggested as potential biomarker candidates for transplantation complications. However, EV isolation from small plasma volumes in clinical biomarker studies using conventional methods is challenging. We therefore investigated if EVs isolated by novel automated acoustic trapping could be developed as potential biomarkers for allo-HSCT complications by performing a clinical proof-of-principle study. RESULTS: Plasma samples were collected from twenty consecutive patients with high-risk/relapsed hematologic malignancies undergoing allo-HSCT before transplantation and post-transplant up to 12 weeks. EVs were isolated from small plasma sample volumes (150 μl) by an automated, acoustofluidic-based particle trapping device, which utilizes a local λ/2 ultrasonic standing wave in a borosilicate glass capillary to capture plasma EVs among pre-seeded polystyrene microbeads through sound scatter interactions. We found that EVs could be reliably isolated from all plasma samples (n = 173) and that EV numbers increased more than 2-fold in the majority of patients after transplantation. Also, sufficient quantities of RNA for downstream microRNA (miRNA) analysis were obtained from all samples and EV miRNA profiles were found to differ from whole plasma profiles. As a proof of principle, expression of platelet-specific miR-142-3p in EVs was shown to correlate with platelet count kinetics after transplantation as expected. Importantly, we identified plasma EV miRNAs that were consistently positively correlated with infection and GvHD, respectively, as well as miRNAs that were consistently negatively correlated with these complications. CONCLUSIONS: This study demonstrates that acoustic enrichment of EVs in a clinical biomarker study setting is feasible and that downstream analysis of acoustically-enriched EVs presents a promising tool for biomarker development in allo-HSCT. Certainly, these findings warrant further exploration in larger studies, which will have significant implications not only for biomarker studies in transplantation but also for the broad field of EV-based biomarker discovery.
BACKGROUND:Infection and graft-versus-host disease (GvHD) are the major causes for mortality and morbidity of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Plasma-derived extracellular vesicles (EVs) contain disease-related proteins, DNAs and RNAs, and have recently been suggested as potential biomarker candidates for transplantation complications. However, EV isolation from small plasma volumes in clinical biomarker studies using conventional methods is challenging. We therefore investigated if EVs isolated by novel automated acoustic trapping could be developed as potential biomarkers for allo-HSCT complications by performing a clinical proof-of-principle study. RESULTS: Plasma samples were collected from twenty consecutive patients with high-risk/relapsed hematologic malignancies undergoing allo-HSCT before transplantation and post-transplant up to 12 weeks. EVs were isolated from small plasma sample volumes (150 μl) by an automated, acoustofluidic-based particle trapping device, which utilizes a local λ/2 ultrasonic standing wave in a borosilicate glass capillary to capture plasma EVs among pre-seeded polystyrene microbeads through sound scatter interactions. We found that EVs could be reliably isolated from all plasma samples (n = 173) and that EV numbers increased more than 2-fold in the majority of patients after transplantation. Also, sufficient quantities of RNA for downstream microRNA (miRNA) analysis were obtained from all samples and EV miRNA profiles were found to differ from whole plasma profiles. As a proof of principle, expression of platelet-specific miR-142-3p in EVs was shown to correlate with platelet count kinetics after transplantation as expected. Importantly, we identified plasma EV miRNAs that were consistently positively correlated with infection and GvHD, respectively, as well as miRNAs that were consistently negatively correlated with these complications. CONCLUSIONS: This study demonstrates that acoustic enrichment of EVs in a clinical biomarker study setting is feasible and that downstream analysis of acoustically-enriched EVs presents a promising tool for biomarker development in allo-HSCT. Certainly, these findings warrant further exploration in larger studies, which will have significant implications not only for biomarker studies in transplantation but also for the broad field of EV-based biomarker discovery.
Authors: Giridharan Ramsingh; Meagan A Jacoby; Jin Shao; Rigoberto E De Jesus Pizzaro; Dong Shen; Maria Trissal; Angela H Getz; Timothy J Ley; Matthew J Walter; Daniel C Link Journal: Blood Date: 2013-09-05 Impact factor: 22.113
Authors: Fatemeh Momen-Heravi; Leonora Balaj; Sara Alian; Pierre-Yves Mantel; Allison E Halleck; Alexander J Trachtenberg; Cesar E Soria; Shanice Oquin; Christina M Bonebreak; Elif Saracoglu; Johan Skog; Winston Patrick Kuo Journal: Biol Chem Date: 2013-10 Impact factor: 3.915
Authors: Sophie Paczesny; Oleg I Krijanovski; Thomas M Braun; Sung W Choi; Shawn G Clouthier; Rork Kuick; David E Misek; Kenneth R Cooke; Carrie L Kitko; Angela Weyand; Daniel Bickley; Dawn Jones; Joel Whitfield; Pavan Reddy; John E Levine; Samir M Hanash; James L M Ferrara Journal: Blood Date: 2008-10-02 Impact factor: 22.113
Authors: Rachel E Crossland; Jean Norden; Mateja Kralj Juric; Kim F Pearce; Clare Lendrem; Louis A Bibby; Matthew Collin; Hildegard T Greinix; Anne M Dickinson Journal: Front Immunol Date: 2017-11-10 Impact factor: 7.561
Authors: Suzanne M Johnson; Clare Dempsey; Catriona Parker; Aleksandr Mironov; Helen Bradley; Vaskar Saha Journal: J Extracell Vesicles Date: 2017-03-10
Authors: Morayma M Temoche-Diaz; Matthew J Shurtleff; Ryan M Nottingham; Jun Yao; Raj P Fadadu; Alan M Lambowitz; Randy Schekman Journal: Elife Date: 2019-08-22 Impact factor: 8.140